Effectiveness And Tolerability Of Pregabalin Usage Among Patients In King Fahad Hospital, Saudi Arabia: A Quasi Longitudinal Study
| dc.contributor.author | Khan, Tahir Mehmood | |
| dc.date.accessioned | 2017-01-10T08:23:36Z | |
| dc.date.available | 2017-01-10T08:23:36Z | |
| dc.date.issued | 2015-05 | |
| dc.description.abstract | A quasi, non-randomized longitudinal study was conducted to assess the effectiveness of 75mg pregabalin post hemodialysis (pHD) once daily orally in treatment-resistant uremic pruritus (UP), and the safety and tolerability among ESRD patients at Aljaber kidney center, King Fahad Hospital, Alahsa Saudi Arabia. Assessment for the severity and intensity of itching was done using the validated Arabic version of 5D- itching scale (α= 0.847, p=0.001, Kaiser- Meyer-Oklin value= 0.810). Safety and tolerability of pregabalin was done by using Naranjo’s algorithm. The effect of the pregabalin over the time was assessed using the generalized linear model. Furthermore, to pinpoint the differences in the effect of pregabalin at different time intervals, generalized estimated equations were used. Finally for the assessment of the association among demographics and UP severity, Monte Carlo simulations were preferred. During the time frame of study about 96 hemodialysis patients were found eligible to be enrolled in the study. However, upon apply the inclusion and exclusion criteria, only 51patients were considered for pregabalin therapy. Assessment of severity and intensity of UP was done at four occasion i.e. baseline assessment (day 0), initial assessment (day 14), assessment of primary outcome (day 28), and assessment of secondary outcome (day 42). At the base line assessment the 5D-IS median score was 19, which reduced to 8 at the day 28 and to 6 on day 42. In comparison to the baseline 5D-IS there was a reduction of 12 points for each patients on day forty two [B= - 12.729 (CI -13.257 – -12.201)]. Keeping in view the reduction of 12.729 in the score revealed that the patient who was suffering from a severe itching got a major relief after using pregabalin 75 mg (PHD) for day 42 (p = <0.001). Among all demographic factors gender was found significantly associated 5D-IS score (B= 0.102, CI -0.498 – 0.720, p= 0.032). Overall, there was a significant improvement in the sleep quality after using pregabalin for 42 days (B= -2.500, p=<0.001). High serum calcium level were found to have high sleep disturbances in comparison to those who are normal (B= 1.302, p= 0.002). In addition improvement in sleep quality among male patients was higher than the female patients (B=-0.216). Assessment of safety of pregabalin revealed that somnolence and dizziness were the two frequents adverse events (AEs) followed by constipation (29.4%), weight gain (11.8%) and edema (9.8%). Naranjo’s quantification for the possibility and probability of AEs reflect that all the events were probable. Significant association were observed among age – weight gain (0.040), disease history in years – blurred vision (0.046) and disease history in years – edema (0.049). Along with these AEs 75 mg pregabalin (pHD) was found and effective treatment option for the management of treatment resistant UP and was well tolerated by all patients. | en_US |
| dc.identifier.uri | http://hdl.handle.net/123456789/3386 | |
| dc.subject | Pharmacy | en_US |
| dc.subject | Chronic renal failure | en_US |
| dc.title | Effectiveness And Tolerability Of Pregabalin Usage Among Patients In King Fahad Hospital, Saudi Arabia: A Quasi Longitudinal Study | en_US |
| dc.type | Thesis | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: